Suppliers / Tianjin Jinjin Pharmaceutical

Tianjin Jinjin Pharmaceutical

China Updated 9 July 2026

Tianjin Jinjin Pharmaceutical is an API manufacturer based in China. It holds 4 active US drug master files across a filed portfolio of 2 molecules. Its GMP standing is certified by MFDS (Korea) and US FDA. Its most recent recorded inspection, by US FDA, closed on 29 March 2024 as VAI.

4
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 29 March 2024 VAI US FDA
  • 9 September 2016 NAI US FDA
  • 17 June 2011 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3003316563

What they file, and where

Molecule Regulators Docs
Hydrocortisone SFDA (Saudi Arabia), US FDA 4
Spironolactone SFDA (Saudi Arabia), US FDA 2

Also appears on these molecule pages

Hydrocortisone API Spironolactone API

Filings and GMP by regulator

Regulator Filings GMP certificates
MFDS (Korea) None 2
US FDA None 1

Questions about Tianjin Jinjin Pharmaceutical

Does Tianjin Jinjin Pharmaceutical hold a US DMF or a CEP?
Tianjin Jinjin Pharmaceutical holds 4 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Tianjin Jinjin Pharmaceutical FDA-registered?
One site operated by Tianjin Jinjin Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Tianjin Jinjin Pharmaceutical's last inspection go?
The most recent inspection on record closed on 29 March 2024 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 3 inspections are on file.
Where does Tianjin Jinjin Pharmaceutical manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Tianjin Jinjin Pharmaceutical make?
2 molecules are on record against Tianjin Jinjin Pharmaceutical, including Hydrocortisone and Spironolactone. Each links through to that molecule's full manufacturer list.
Which regulators recognise Tianjin Jinjin Pharmaceutical's GMP?
Current GMP certificates are on record from MFDS (Korea) and US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Tianjin Jinjin Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 29 March 2024.

Comparable suppliers

EUROAPI shares 2 molecules Tianjin Tianyao Pharmaceuticals shares 2 molecules Lupin shares 1 molecule Curia shares 1 molecule Dasami Lab shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates